Prima Secures European Patent Grant for Lead Product IMP321 in Cancer
November 21 2017 - 6:07PM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima”, the “Company”)
announces the grant of patent number 2604275 entitled “Use of
Recombinant LAG-3 or the Derivatives thereof for Eliciting Monocyte
Immune Response” by the European Patent Office.
This European patent was filed as a divisional application and
follows the grant of the European parent patent, which was issued
in August 2013.
The claims of this new patent are geared toward the use of
Prima’s lead candidate IMP321 in combination with a
chemotherapeutic agent for the treatment of cancer. According
to the claims, IMP321 elicits a monocyte-mediated immune response
and is administered before, with, or subsequent to administration
of the chemotherapeutic agent. Importantly, these granted
claims support the application of IMP321 in Prima’s AIPAC clinical
trial in metastatic breast cancer in Europe.
The patent expiry date is 3 October 2028.
About Prima BioMedPrima announced a rebranding
of the Company from Prima BioMed Ltd to Immutep Ltd following
shareholder approval at its Annual General Meeting on 17th November
2017.
Subject to regulatory approvals, the effective date for the name
change and the ticker symbols on the ASX and NASDAQ will be on or
around the commencement of trading on 1st December 2017 with the
new ASX ticker symbol of ‘IMM’ and new NASDAQ ticker symbol of
‘IMMP’.
A fact sheet has been prepared for shareholders regarding the
change of name which can be accessed on our website.
For further information please
contact:
Australian Investors/Media:Mr
Matthew Gregorowski, Citadel-MAGNUS+61 2 8234 0105;
mgregorowski@citadelmagnus.com
U.S. Investors:
Jay Campbell, Vice President of Business Development and
Investor Relations, Prima BioMed+1 (917) 860-9404;
jay.campbell@primabiomed.com.au
Matthew Beck, The Trout Group LLC+1 (646) 378-2933;
mbeck@troutgroup.com
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immutep Limited (NASDAQ:PBMD)
Historical Stock Chart
From Sep 2023 to Sep 2024